US EditionPharmacies Warn of Unsustainable Demand for Weight Loss Medication
- The National Pharmacy Association warns that the rising demand for weight loss injections may be unsustainable due to a mismatch between public interest and clinical suitability for the treatments.
- A recent poll shows that 21% of participants tried to access weight loss treatments in the past year, with 35% of those aged 16 to 34 seeking such treatments.
- The NPA calls for regulations to protect patients buying weight loss medications online and to ensure proper medical consultations.
- NPA Chairman Olivier Picard emphasizes the importance of appropriate treatment prescribing and mentions that pharmacists can provide valuable support in weight loss management.
11 Articles
11 Articles
The Independent
The Independent (US)Pharmacy warning of unsustainable demand for weight loss medication
Spiralling demand could see people being tempted to resort to unregulated online supplier
Obesity has become one of the major health challenges of the 20th century. Beyond the aesthetic impact, it is associated with increased risk of cardiovascular diseases, type 2 diabetes and various types of cancer. In recent years, regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have approved six specific drugs to treat obesity. Among them are orlistat, phentermine-topiramate and semaglutide, indicated in patients with o…
Around 64 percent of Britons aged 25 to 34 say they would be willing to take weight-management drugs if they were covered by health insurance, compared to 41 percent across all age groups.
Express & Star
Shropshire StarBooming demand for weight loss drugs is unsustainable, pharmacists warn
Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
